Biota Holders, How about an economic cost/benefit analysis of the benficiaries from use of Relenza in treating influenza:
1 Government (& Health Care Funds) - reduced time off work - increased productivity - reduced hospitalisation - emergency dept visits - reduced critical care unit costs (I/V Relenza) - reduced long term impact on some individuals health - reduced deaths (and loss of long term productivity) - reduced spread of infection - reduced infant deaths (I/V Relenza) - resistance issues with Tamiflu - low cost - about $50 per course (less for governments) - long life product - doesnt require refrigeration - easily dispensed (inhalation), straight to site of activity in lungs - non-toxic, well tolerated,rapid acting - reduced stillbirths in pregnant women - reduced impact on schools, sporting events, retirement villages & nursing homes - reduced emergency disease control responses - reduced risk to armed forces - improved preparation for a Pandemic - 6 month delay in producing vaccine against new influenza strains (too late) - Relenza active against all strains of influenza - seasonal influenza outbreaks annual usually in winter in Northern and Southern Hemispheres, pandemics every 10-25 years.
2 Private individual - all of the above plus - reduced duration illness - reduced impact on business - reduced impact on leisure activities including costly holidays - low cost insurance policy re long term impact, hospitalisation & potentially death - reduced risk to pregnant women - reduced risk to children and elderly
Where is the publicity, publications, lobbying on the economic benefits?
Regards Kangaroo1
BTA Price at posting:
0.0¢ Sentiment: Hold Disclosure: Held